2026-06-08T09:50:58Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1034472025-09-16T14:44:06Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Cabañas Morafraile, Esther author Saiz Ladera, Cristina author Nieto Jiménez, Cristina author Győrffy, Balázs author Nagy, Adam author Velasco Díez, Guillermo author Pérez Segura, Pedro author Ocaña, Alberto author 2023 <jats:p>Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified in 8–15% of the patients. In this work we interrogated a public dataset to explore the surfaceome of these tumors and found that several genes, such as GP2, CLDN18, AQP5, TM4SF4, NTSR1, VNN1, and CD109, were upregulated. By performing gene set enrichment analysis, we also identified a striking upregulation of genes (CD74, LAG3, HLA-DQB1, HLA-DRB5, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DRA, HLA-DOA, FCGR2B, HLA-DQA1, HLA-DRB1, and HLA-DPA1) associated with antigen processing and presentation via MHC class II. Likewise, we found a strong correlation between PD1 and PD(L)1 expression and the presence of genes encoding for proteins involved in antigen presentation such as CD74, HLA-DPA1, and LAG3. Furthermore, a similar association was observed for the presence of dendritic cells and macrophages. Finally, a low but positive relationship was observed between tumor mutational burden and neoantigen load. Our findings support the idea that a therapeutic strategy based on the targeting of PD(L)1 together with other receptors also involved in immuno-modulation, such as LAG3, could help to improve current treatments against BRAF-mutated CRC tumors.</jats:p> 1718-7729 10.3390/curroncol30030196 https://hdl.handle.net/20.500.14352/103447 https://doi.org/10.3390/curroncol30030196 https://www.mdpi.com/1718-7729/30/3/196 Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers